At the news
? BEARISHIMPACT 5/10 PRESS-RELEASE filed Nov 4, 2026 at 07:30 ET
Harmony Biosciences reported Q3 2026 WAKIX net revenue of $268.9M (+12% YoY), slightly below the $272.1M consensus. GAAP diluted EPS of $0.81 missed the $1.47 consensus, driven by a $25M milestone charge and higher royalties. The company reiterated full-year revenue guidance of $1.0B-$1.04B and highlighted positive early BP-205 MAD study data.
- Q3 2026 WAKIX net revenue $268.9M, +12% YoY from $239.5M, vs consensus $272.1M
- GAAP diluted EPS $0.81, down from $0.87 YoY, vs consensus $1.47
- Net income $48.2M vs $50.9M YoY; operating income $54.2M vs $65.5M YoY
- Cost of product sold rose to 30% of revenue from 25% YoY, driven by new Novitium royalties
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access